Preliminary analysis in HEK293 and HeLa cells demonstrated, that MIR-22-3p targets GBA and the GBA pseudogene GBAP1. These findings were validated in 35 days old iPSC-derived DAn from six controls and four PD patients carrying GBA mutations according to the differentiation protocol of Kriks et al. (2011). This evidence concerns the gene GBA1 and Parkinson disease.